ABCL News and Press, AbCellera Biologics Inc. From 08/03/22

AbCellera Biologics ( NASDAQ: ABCL ) has entered into a partnership with Atlas Ventures to discover therapeutic antibodies for up to three drug targets . Terms call for Atlas to have the right to develop and commercialize therapeutic antibodies resulting from the colla...

Atlas' stealth-stage company will leverage AbCellera’s technology to start and advance new drug programs with enhanced speed and capital efficiency AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodi...

AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm...

A newly published study indicates that Evusheld, a monoclonal antibody therapy developed by AstraZeneca ( NASDAQ: AZN ) which is available in the U.S. for pre-exposure prophylaxis of COVID-19 might be less effective against new sub lineages of Omicron. The study was designed...

AbCellera (Nasdaq: ABCL) will announce its second quarter 2022 financial results on Tuesday, August 9, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed thro...

The Health Care sector of the S&P 500 was in the red this month, with the Health Care Select Sector SPDR ETF ( XLV ) finishing 3% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concern AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an ...

Eli Lilly ( NYSE: LLY ) announced a modified purchase agreement with the U.S. government on Wednesday to deliver an extra 150,000 doses of its COVID-19 antibody therapy, bebtelovimab for approximately $275M. The supplies are expected begin immediately and complete on or be...

Stanley Druckenmiller’s 13F portfolio value decreased from $2.93B to $2.31B this quarter. Duquesne added Teck Resources and Coterra Energy while dropping Alphabet, Carvana, and Palo Alto Networks. They also added a large short position in S&P 500 index through Puts. The...